Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients

Regina Juanbeltz, Iván Martínez-Baz, Ramón San Miguel, Silvia Goñi-Esarte, Juan Manuel Cabasés and Jesús Castilla

PLOS ONE, 2018, vol. 13, issue 10, 1-15

Abstract: Background: Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the change in health-related quality of life (HRQoL) among patients successfully treated, and to identify predictors of this variation. Methods: In a prospective observational study, patients with chronic hepatitis C who started DAA therapy between May 2016 and April 2017 completed the EQ-5D-5L questionnaire at baseline and 12 weeks after the end of therapy before knowing the virological result. Analysis included all patients with SVR. Results: Median baseline EQ-5D-5L scores of the 206 enrolled patients were 0.857 utility and 70.0 visual analogue scale (VAS). Following SVR, a reduction occurred in the proportion of patients with mobility problems (35% vs 24%, p = 0.012), pain/discomfort (60% vs 42%, p

Date: 2018
References: Add references at CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205277 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 05277&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0205277

DOI: 10.1371/journal.pone.0205277

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().